Author Affiliations: Departments of Dermatology (Drs Aouidad, Fite, Crickx, and Descamps) and Pathology (Drs Marinho and Deschamps), APHP, Hospital Bichat-Claude Bernard, Paris VII Denis Diderot University, Paris, France.
Cases of drug-induced bullous pemphigoid (BP) have been reported in association with spironolactone, furosemide, chloroquine, β-blocker, or antibiotic treatment.1,2 We report the case of a patient who developed a severe BP after starting therapy with a dipeptidyl peptidase-4 (DPP-4) inhibitor (vildagliptin), an incretin-based drug used to treat type 2 diabetes mellitus.
Aouidad I, Fite C, Marinho E, Deschamps L, Crickx B, Descamps V. A Case Report of Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors. JAMA Dermatol. 2013;149(2):243–245. doi:10.1001/jamadermatol.2013.1073
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: